Insider · CIK 0001763999
Stuart Holden
Files at URGN (UroGen Pharma Ltd.). First filing -, latest -.
In brief
Stuart Holden files SEC Form 4 as director at URGN (UroGen Pharma Ltd.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Stuart Holden has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | URGN UroGen Pharma Ltd. | AGrant or award Stock Option (right ot buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 24, 2026 |
| Nov 26, 2025 | URGN UroGen Pharma Ltd. | MOption exercise ordinary shares | +2,000 | - | - | 2,000 | Dec 1, 2025 |
| Nov 26, 2025 | URGN UroGen Pharma Ltd. | MOption exercise Restricted Stock Unitderivative | -2,000 | $0.00 | $0 | 6,000 | Dec 1, 2025 |
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | AGrant or award Stock Option (right ot buy)derivative | +10,000 | $0.00 | $0 | 10,000 | Aug 27, 2025 |
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | AGrant or award Restricted Stock Unitderivative | +8,000 | $0.00 | $0 | 8,000 | Aug 27, 2025 |
Questions about Stuart Holden
Answered from the filings on this page, as of the latest one.
Is Stuart Holden buying or selling?
Stuart Holden has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Stuart Holden's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Stuart Holden has 0.
Where does Stuart Holden file Form 4?
Stuart Holden has filed Form 4 at URGN (UroGen Pharma Ltd.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.